On Thursday, Kühne+Nagel announced that it will ensure the worldwide distribution of the Moderna vaccine doses from production sites based in Europe. This includes distribution to markets in Europe, Asia, the Middle East and Africa, as well as parts of the Americas.
“Kuehne+Nagel will use its network of more than 230 operations worldwide to distribute the vaccine via road and air. In Europe alone, the company operates its own fleet of over 200 dedicated pharmaceutical transport vehicles. At all stages of transport and storage, product integrity at the required temperature of -20°C will be maintained,” said the firm on Thursday.
The financial terms of the agreement were not disclosed.
Swiss involvement
Moderna has made good use of Swiss know-how to help manufacture and roll out its vaccine. Quickstat, Kühne+Nagel’s clinical trial logistics subsidiary, has already been part of the supply chain for the Moderna vaccine, having supported the supply logistics for Phase II and Phase III clinical trials in the US.
Swiss pharma company Lonza will produce the Moderna vaccine in Switzerland for non-US markets. It is building three vaccine production lines in the western Swiss town of Visp at a cost of $210 million (CHF191 million) to supply 300 million doses annually for the rest of the world. In parallel, new production lines at Lonza’s site in Portsmouth, New Hampshire, will start making vaccine ingredients exclusively for the US.
On Wednesday, the European Union granted a conditional approval for the Moderna vaccine. However, Switzerland’s medical regulator has not yet given it the green light even though the Alpine nation was one of the early buyers. Switzerland will get 4.5 million doses of the vaccine, enough to vaccinate 2.25 million people if, as expected, two doses are needed per patient.
Protein in abdominal fat could help shape obesity treatment
This content was published on
The study analysed fat cells from different locations in the body, and found that those in the abdomen have unique properties.
North African asylum claims fall after rapid Swiss processing
This content was published on
The accelerated procedure, now out of its test phase, has resulted in a significant drop in applications from North African countries.
This content was published on
The artist's song "The Code" focuses on their journey as a nonbinary individual. It is one of the favourites to win this year's contest.
Swiss climate activists block vehicles near Gotthard tunnel
This content was published on
Around ten climate activists briefly blocked the A2 motorway near the northern entrance of the Gotthard tunnel on Thursday.
Watches belonging to Michael Schumacher up for auction
This content was published on
Schumacher's family is auctioning off eight rare watches from his collection in Geneva. The Christie's auction will take place on Monday.
Joya Marleen and Baschi named best solo acts at Swiss Music Awards
This content was published on
St. Gallen singer Joya Marleen and Baschi from Basel were named artists of the year at the Swiss Music Awards 2024 on Wednesday night.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Covid-19 vaccine: Why we still have a long wait ahead
This content was published on
Countries have started rolling out a Covid-19 vaccine, but it will likely take years to manufacture doses at the scale needed to reach the masses.
Swiss factory rushes to prepare for Moderna Covid-19 vaccine
This content was published on
Workers are racing to set up production lines at the Lonza factory in Visp to be able to start making a vaccine for US firm Moderna later this year.
Why Switzerland’s Moderna Covid-19 vaccine deal is risky
This content was published on
Switzerland’s vaccine order – its first such move – is a sign that it holds little hope for fair distribution of a Covid-19 shot.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.